Zenotech Laboratories Limited (532039) Fair Value & Analysis
Other · IN · Market cap ₹2.1B
Fair value as of: Jul 4, 2026
From 13 valuation models · updated today
Share price +2.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹34.29 – ₹63.81 · fair‑value band ₹8.08 – ₹9.15 · the ₹45.91 price screens above the ₹8.64 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zenotech Laboratories Limited (532039) currently trades at ₹45.91, while our model-based Fair Value estimate is ₹8.64 — implying the stock looks roughly 81.2% overvalued today. We read business quality at 52/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Zenotech Laboratories Limited generated revenue of ₹197M at a net margin of 22.1%. Revenue declined 58.8% year over year. It earns a return on equity of 9.7%. Net debt stands at ₹35.9M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Zenotech Laboratories Limited operates as a pharmaceutical specialty generic injectables company in India. The company manufactures oncology, biotechnology, and general injectable products, such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony-stimulating factor (GMCSF). Its injectable product portfolio primarily serves therapy areas, such as oncology and anesthesiology. The company was formerly known as Sunline Technologies Limited and changed its name to Zenotech Laboratories Limited in August 2004. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Zenotech Laboratories Limited reported revenue of ₹396M in FY2026 versus ₹366M in FY2022, a compound +2.0%/yr. Reported net income was −₹10.7M in FY2026.
Is 532039 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Zenotech Laboratories Limited (532039) undervalued?
What is the fair value of 532039?
What is the quality score of 532039?
What is the revenue of Zenotech Laboratories Limited (532039)?
What is the net profit margin of 532039?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.